Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
Not yet recruiting · NCT07765836 · Registry updated 2026-08-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Digestive System Diseases, Digestive System Neoplasms, Fanconi anemia complementation group D1, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07765836 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| Lustgarten Foundation | 12 |
| Massachusetts General Hospital | 758 |
| Xilio Development, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |